Literature DB >> 28795397

Kinase Inhibitors: The Reality Behind the Success.

Jae Yoon Jeon1, Alex Sparreboom1, Sharyn D Baker1.   

Abstract

Tremendous progress has been made by utilizing kinase inhibitors in oncology, and these agents continue to pave the way into other areas of medicine. There are, however, many challenges to the application of kinase inhibitors due to inherent shortcomings of the drugs and lack of comprehensive understanding of tumor and disease biology. The future fate of kinase inhibitors, however, is bright, as evidenced from ongoing efforts to increase their efficacy while remediating their weaknesses in order to provide the best quality of care to patients.
© 2017 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28795397      PMCID: PMC6069597          DOI: 10.1002/cpt.815

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  11 in total

Review 1.  The protein kinase complement of the human genome.

Authors:  G Manning; D B Whyte; R Martinez; T Hunter; S Sudarsanam
Journal:  Science       Date:  2002-12-06       Impact factor: 47.728

2.  Small-molecule kinase inhibitors: an analysis of FDA-approved drugs.

Authors:  Peng Wu; Thomas E Nielsen; Mads H Clausen
Journal:  Drug Discov Today       Date:  2015-07-23       Impact factor: 7.851

Review 3.  Targeting cancer with small molecule kinase inhibitors.

Authors:  Jianming Zhang; Priscilla L Yang; Nathanael S Gray
Journal:  Nat Rev Cancer       Date:  2009-01       Impact factor: 60.716

Review 4.  FDA-approved small-molecule kinase inhibitors.

Authors:  Peng Wu; Thomas E Nielsen; Mads H Clausen
Journal:  Trends Pharmacol Sci       Date:  2015-05-12       Impact factor: 14.819

Review 5.  Targeting cancer with kinase inhibitors.

Authors:  Stefan Gross; Rami Rahal; Nicolas Stransky; Christoph Lengauer; Klaus P Hoeflich
Journal:  J Clin Invest       Date:  2015-05-01       Impact factor: 14.808

6.  Integrating clinical pharmacology concepts in individualized therapy with tyrosine kinase inhibitors.

Authors:  C D Drenberg; S D Baker; A Sparreboom
Journal:  Clin Pharmacol Ther       Date:  2013-03       Impact factor: 6.875

7.  Rational design of inhibitors that bind to inactive kinase conformations.

Authors:  Yi Liu; Nathanael S Gray
Journal:  Nat Chem Biol       Date:  2006-07       Impact factor: 15.040

Review 8.  Pharmacokinetic considerations for new targeted therapies.

Authors:  S D Baker; S Hu
Journal:  Clin Pharmacol Ther       Date:  2008-12-17       Impact factor: 6.875

Review 9.  Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology.

Authors:  Remy B Verheijen; Huixin Yu; Jan H M Schellens; Jos H Beijnen; Neeltje Steeghs; Alwin D R Huitema
Journal:  Clin Pharmacol Ther       Date:  2017-09-07       Impact factor: 6.875

Review 10.  Application of Liquid Biopsies in Cancer Targeted Therapy.

Authors:  S Sumanasuriya; M B Lambros; J S de Bono
Journal:  Clin Pharmacol Ther       Date:  2017-07-29       Impact factor: 6.875

View more
  3 in total

Review 1.  Role of SLC transporters in toxicity induced by anticancer drugs.

Authors:  Kevin M Huang; Muhammad Erfan Uddin; Duncan DiGiacomo; Maryam B Lustberg; Shuiying Hu; Alex Sparreboom
Journal:  Expert Opin Drug Metab Toxicol       Date:  2020-04-26       Impact factor: 4.481

2.  Kinome inhibition reveals a role for polo-like kinase 1 in targeting post-transcriptional control in cancer.

Authors:  Qamraa H Al-Qahtani; Walid N Moghrabi; Suhad Al-Yahya; Latifa Al-Haj; Maher Al-Saif; Linah Mahmoud; Falah Al-Mohanna; Norah Al-Souhibani; Ayodele Alaiya; Edward Hitti; Khalid S A Khabar
Journal:  Mol Oncol       Date:  2021-02-01       Impact factor: 6.603

Review 3.  The Genetics of Parkinson's Disease and Implications for Clinical Practice.

Authors:  Jacob Oliver Day; Stephen Mullin
Journal:  Genes (Basel)       Date:  2021-06-30       Impact factor: 4.096

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.